Stryker Co. (NYSE:SYK) Shares Sold by Bath Savings Trust Co

Bath Savings Trust Co reduced its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 0.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,702 shares of the medical technology company's stock after selling 710 shares during the period. Stryker makes up about 4.3% of Bath Savings Trust Co's investment portfolio, making the stock its 4th largest position. Bath Savings Trust Co's holdings in Stryker were worth $41,953,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Moody National Bank Trust Division purchased a new position in shares of Stryker during the first quarter valued at $212,000. Versant Capital Management Inc boosted its position in Stryker by 35.1% during the 1st quarter. Versant Capital Management Inc now owns 1,515 shares of the medical technology company's stock worth $564,000 after acquiring an additional 394 shares during the period. jvl associates llc acquired a new stake in Stryker during the 1st quarter worth about $245,000. Rempart Asset Management Inc. increased its holdings in shares of Stryker by 4.2% in the 1st quarter. Rempart Asset Management Inc. now owns 51,589 shares of the medical technology company's stock valued at $19,204,000 after purchasing an additional 2,093 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Stryker by 2.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 69,294 shares of the medical technology company's stock worth $25,795,000 after purchasing an additional 1,653 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 5.20% of the company's stock.

Stryker Stock Performance

Shares of NYSE:SYK traded up $0.51 on Friday, reaching $382.86. 1,993,145 shares of the company's stock were exchanged, compared to its average volume of 1,339,482. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a fifty day moving average of $368.77 and a 200-day moving average of $376.22. The company has a market capitalization of $146.13 billion, a price-to-earnings ratio of 49.34, a PEG ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the previous year, the company posted $2.50 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research analyst reports. Truist Financial boosted their price objective on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Evercore ISI cut their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Roth Mkm upped their target price on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.